AbbVie is transitioning from legacy drugs to newer blockbusters, acquiring psychedelic drug candidates, and expanding API manufacturing capacity.
2 reports, 2 independent
Updated Sep 2
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 4
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie is transitioning from legacy drugs to newer blockbusters, acquiring psychedelic drug candidates, and expanding API manufacturing capacity.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- AbbVie acquired Gilgamesh Pharmaceuticals' psychedelic drug program, with analysts noting the sector is nearing a tipping point.Sub-event
- Gilgamesh Pharmaceuticals acquired Bretisilocin, adding depth to Neuro's drug development pipeline.Sub-event
AbbVie is undergoing strategic shifts, including acquisitions and manufacturing expansion.1 source
AbbVie expands into psychedelic drugs; Agrify acquires cannabis brands.1 source
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
Gilgamesh Pharmaceuticals
American pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyAbbVie Inc. (ABBV) Acquires Psychedelic Drug Developer Gilgamesh for $1.2B, Enters Mental Health Market We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Ab
- Market ExclusiveWeekly Roundup on the Cannabis Sector & Psychedelic Sector Key Takeaways; Cannabis Sector Green Thumb Sold Iconic Brands to Agrify, Which Will Rebrand as RYTHM, Inc. MTL Cannabis Delivered Steady Q1